Life Sciences Tools and Services
Company Overview of ForteBio, Inc.
ForteBio, Inc. develops instrumentation for biotherapeutic drug discovery and development. It offers analytical systems that enable real-time analysis of biomolecular interactions, such as protein quantification and characterization of protein-protein interactions, etc. in micro-volume sample sizes. The company offers Octet systems that include instruments, biosensors, reagents, and assay kits for the analysis of biomolecular interactions, as well as to enable real-time and label-free analysis for the determination of affinity, kinetics, and concentration. Its Octet systems also enable large molecule characterization and small molecule and fragment analysis. The company also offers BlItz Sys...
1360 Willow Road
Menlo Science & Technology Park
Menlo Park, CA 94025
Founded in 2001
Key Executives for ForteBio, Inc.
Chief Executive Officer, President and Director
Vice President of Product Development & Operations and General Manager
Vice President of China Operations
Compensation as of Fiscal Year 2014.
ForteBio, Inc. Key Developments
Pall ForteBio LLC Launches Octet K2 System
Mar 31 15
Pall ForteBio LLC announced the launch of the Octet K2 system, a new entry point into the Octet line of label-free interaction analysis systems. Available in Asia and Europe, the Octet K2 system offers high-performance, budget-friendly kinetic characterization of antibody, protein, and small molecule binding interactions. Using Pall ForteBio’s Bio-Layer Interferometry (BLI) technology, the systems in the Octet family offer a fluidics-free alternative to surface plasmon resonance (SPR) with a variety of off-the-shelf Dip and Read™ biosensors for more rapid assay development and optimization. The Octet K2 system increases accessibility to BLI in a low-throughput, 2-channel instrument that provides exquisite binding affinity data, even for molecules down to 150 daltons in size.
ForteBio, Inc. Launches New Interaction Analysis System
Sep 20 13
ForteBio, Inc. has launched the Octet HTX system, the new member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates, the company said. Octet systems provide unique insights into drug-target binding interactions, insights that are used to fine-tune the affinity and specificity of drug molecules. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously, a capability offered by no other stand-alone label-free platform. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as 2 minutes.
Avacta Group plc Announces Expansion of Collaboration with Fortebio
Jul 25 13
Avacta Group plc announced that it has extended its commercial collaboration with ForteBio. Avacta has entered into a distribution agreement with ForteBio for the sale of Optim, the group's protein analysis product, in China, Hong Kong and Taiwan. Optim has been developed to accelerate and reduce the cost of drug development by providing early analysis of compounds to identify the best candidates and to define the optimal processing conditions. In the critical stages of pre-formulation, stability testing and formulation of biopharmaceutical drugs, Optim delivers vital information tens of times faster than other approaches, using sample sizes less than a hundredth the size of those needed by existing techniques. Optim comprises a benchtop instrument, analysis software and a single-use sample holder that leads to recurring consumables revenues.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|